Recursion Pharmaceuticals RXRX Insider Ownership

Updated Oct 11, 2026

Over the trailing 12 months, RXRX insiders sold $8.22 million worth of shares (2Mn shares) in open-market trades, with no open-market purchases.

• A count shows 6 insiders selling RXRX stock on the open market over the past 12 months and none buying.
• Blake Borgeson (Director) led open-market sales of Recursion Pharmaceuticals stock over the past 12 months with $4.34 million (1.07Mn shares), most recently on October 6, 2026.
• Beyond open-market trades, insiders at Recursion Pharmaceuticals received 2.88Mn shares in stock awards, acquired 785K shares through option exercises and conversions, gave up 500.06K shares to cover taxes or exercise prices and gave away 100K shares as gifts in the last 12 months.
• Business Quant data puts insider holdings in RXRX at 22.69Mn shares across insiders' latest Form 4 filings, or 4.26% of the 532.46Mn shares outstanding; that total is down 1.58% from 23.06Mn shares at the end of Q2 2026 and up 5.10% from 21.59Mn shares at the end of Q3 2025.
• Recursion Pharmaceuticals insiders hold 20.03Mn shares directly (88.25% of their total) and 2.67Mn shares (11.75%) indirectly, through entities such as trusts and partnerships.
• Business Quant counts 14 insiders with holdings in Recursion Pharmaceuticals stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Recursion Pharmaceuticals' top three insider holders by shares held are Blake Borgeson (Director, 6.11Mn shares), Christopher Gibson (Director, 5.97Mn shares) and Dean Y. Li (Director, 3.32Mn shares).
• Blake Borgeson alone accounts for 26.92% of the shares held by Recursion Pharmaceuticals insiders.
• Institutional investors owned 67.96% of RXRX shares as of Q2 2026, per their 13F filings.
• Over the past 12 months, 11 insiders reported transactions in Recursion Pharmaceuticals stock in 71 Form 4 filings.
• These insider figures for Recursion Pharmaceuticals are based on Form 4 filings through October 7, 2026.